Beta

Cardiol therapeutics inc.CRDL.US Overview

US StockHealthcare
(No presentation for CRDL)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

CRDL AI Insights

CRDL Overall Performance

CRDL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CRDL Recent Performance

-2.14%

Cardiol therapeutics inc.

-1.10%

Avg of Sector

-0.49%

S&P500

CRDL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check CRDL's Trend

CRDL Key Information

CRDL Valuation Metrics

CRDL Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Price of CRDL

CRDL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CRDL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1014.87
PB Ratio
11.96
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1014.87
PB Ratio
11.96
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CRDL's latest earnings report released?

    The most recent financial report for Cardiol therapeutics inc. (CRDL) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CRDL's short-term business performance and financial health. For the latest updates on CRDL's earnings releases, visit this page regularly.

  • How much debt does CRDL have?

    As of the end of the reporting period, Cardiol therapeutics inc. (CRDL) had total debt of 125.52K, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CRDL have?

    At the end of the period, Cardiol therapeutics inc. (CRDL) held Total Cash and Cash Equivalents of 21.42M, accounting for 0.91 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CRDL's EPS continuing to grow?

    According to the past four quarterly reports, Cardiol therapeutics inc. (CRDL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CRDL?

    Cardiol therapeutics inc. (CRDL)'s Free Cash Flow (FCF) for the period is -5.23M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.63% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.